drugset / Trial / NCT06019130
Nivolumab in Children and Adults With Nasopharyngeal Carcinoma
Phase 2
Recruiting
57 enrolled
German Society for Pediatric Oncology and Hematology GPOH gGmbH
Deutsche Krebshilfe e.V., Bonn (Germany) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess whether the addition of the immune checkpoint inhibitor Nivolumab to induction chemotherapy will increase the percentage of patients with a complete response on MRI and PET after 3 cycles of induction therapy.
Timeline
- Start
- 2023-01-10
- Primary completion
- 2026-01-09
- Completion
- 2028-01-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 4.5 mg/kg | — |
| Background | Cisplatin | Other / unclassified | 20 mg/m2 | — |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Background | Interferon beta-1a | Protein / enzyme biologic | 6e+06 iu | Subcutaneous |
| Background | fluorouracil | Small molecule | 1000 mg/m2 | — |